The Rising Tide of AI in Pharma: opportunities and Challenges
Artificial intelligence is transforming the pharmaceutical industry, speeding up processes from target identification to patient stratification. While AI promises quicker drug development and better clinical trials, it also threatens jobs like data curators and model trainers. The sector’s heavy regulation demands careful governance, ensuring human expertise remains essential.
Adoption rates vary across the industry. Large companies can invest in advanced AI models, while mid-sized firms must weigh costs against automation benefits. The key question is not whether to use AI, but how to integrate it into existing systems without compromising safety and effectiveness.
Babak Hodjat, Cognizant’s chief AI officer, counters fears surrounding automation tools from startups like Anthropic. In a recent interview, he stated that AI systems require significant engineering, integration, and governance, rather than being a simple out-of-the-box solution.
Cognizant, which has over 70% of its workforce in India, recently exceeded revenue expectations, driven by demand for AI consulting. This reflects a broader trend: companies still rely on specialists to adapt AI to existing IT systems and ensure compliance with strict regulations.
Hodjat’s views are shared by peers at Tata Consultancy Services and Wipro, who believe AI adoption will increase the need for software consultants. As AI becomes integral to drug development, the complexity of integrating it with existing systems will create demand for engineers and data scientists who can turn AI outputs into actionable decisions.
Cognizant, which has over 70% of its workforce in India, recently exceeded revenue expectations, driven by demand for AI consulting.
The Future of IT Services: Adapting to New AI Realities
The IT services industry faces a pivotal moment. Traditional models of large offshore teams are challenged by a need for AI-driven solutions that require technical skills and ethical oversight. In pharmaceuticals, strict regulations demand that AI models be explainable and auditable, which cannot be delegated to generic AI services.
As a result, service providers are reshaping their strategies. They are investing in training programs that combine pharmacology with machine learning, establishing AI governance practices, and partnering with startups to deliver tailored solutions. This approach reduces the risks of opaque AI deployments and opens new career paths for professionals skilled in both science and technology.
However, the industry must also address the human impact of automation. Recent layoffs at companies like WiseTech Global and Tata Consultancy Services highlight the need for proactive talent management, including reskilling and continuous learning, to keep pace with technological changes.
Critical Insights: Navigating the AI Paradox
The pharmaceutical industry’s journey with AI presents both opportunities and challenges. AI can enhance efficiency in areas like predictive toxicology and clinical trial monitoring, but it also requires human oversight from engineers, scientists, and compliance officers.
Recent layoffs at companies like WiseTech Global and Tata Consultancy Services highlight the need for proactive talent management, including reskilling and continuous learning, to keep pace with technological changes.
Cognizant’s experience highlights that automation will not eliminate the need for expertise; it will increase it. Companies that treat AI as a simple solution may overlook the integration and governance needed to maintain safety and data integrity. Those that foster collaboration between AI vendors and experienced service firms will be better positioned to succeed.
The Long-Term View: Shaping Careers in an AI-Infused Pharma Landscape
For professionals in pharmaceutical research, AI will change job roles rather than eliminate them. Data scientists must now grasp pharmacokinetics and clinical endpoints, while traditional chemists and biologists must learn to interpret algorithmic recommendations.
Firms like Cognizant are now seeking talent that bridges life sciences and analytics. They prioritize candidates with backgrounds in biotechnology and machine learning or clinical trial management and cloud expertise. This trend indicates that the most valuable employees will be those who can turn AI insights into compliant, market-ready products.
For the pharmaceutical sector, AI will enhance human expertise, reshape careers, and drive innovation—if the industry embraces a collaborative approach that keeps skilled professionals involved.
NIELIT's launch of a digital university platform and five new centers for AI and cybersecurity marks a significant step in educational reform in India.
Looking ahead, the future of AI in pharma will depend on regulatory frameworks and technological advancements. As guidelines for AI-assisted drug development evolve, the demand for governance specialists will grow alongside model developers. The balance between automation and safety will rely on effective human-AI collaboration.
Ultimately, fears that AI tools from startups like Anthropic will make traditional IT services obsolete are unfounded. As Babak Hodjat notes, sophisticated AI requires careful mapping, integration, and oversight. For the pharmaceutical sector, AI will enhance human expertise, reshape careers, and drive innovation—if the industry embraces a collaborative approach that keeps skilled professionals involved.
Entrepreneurship
Artificial Intelligence
